Notably, anti‐CD38 mAbs, Daratumumab (Dara) and Isatuximab (Isa) have demonstrated substantial efficacy, which has led to their initial FDA approval for relapsed/refractory multiple myeloma (RRMM) [7]. Here, CD38 is linked to plasma cell myeloma.